In order to investigate the effects of the cal cium entry blocker lidoflazine on neurologic outcome in primates following an episode of global brain ischemia. 12 pigtail monkeys (Macaca nemestrina) were subjected to 17 min of complete cerebral ischemia, foll owed by 48 h of intensive care treatment and daily neurologic evaluations for 96 h. The monkeys were randomly assigned to re ceive, in a blind fashion, either lidoflazine 1. 0 mg/kg (n = 6) or inactive lidoflazine solvent (n = 6) at 5 min. 8 h, and 16 h postischemia. One monkey in the lidoflazine group did not meet preestablished protocol criteria and was ex cluded from data analysis. The remaining monkeys were well matched for age, sex. and other physiologic vari-Abbreviations used: NA, norepinephrine; PEEP. positive end expiratory pressure. 366 abIes. Neurologic outcome was not significantly different between the lidoflazine-and placebo-treated groups (p > 0.5). No monkey in either group achieved a normal neu rologic exam by 96 h postischemia. Three lidoflazine treated monkeys and two placebo-treated monkeys died prior to the 96-h neurologic evaluation. These deaths were judged to be neurologic in origin. The authors con clude that lidoflazine does not improve neurologic out come in primates when administered after 17 min of com plete cerebral isc hemia. Key Words: Cal cium entry blocker -Cerebral ischemia -Cerebral protection -Li doflazine.
Sixty-seven percent of patients who are success fully resuscitated from cardiac arrest sustain either severe neurologic dysfunction or remain comatose (Brain Resuscitation Clinical Tr ial I Study Group, 1986) . This dismal outcome accounts for the con tinued active search for better brain-oriented post resuscitation therapy. Many studies have been de signed to evaluate the effects of various agents or interventions in attenuating neurologic deficits fol lowing cerebral ischemic injury. Recently, much in terest has been concentrated on the calcium entry blockers for treating cerebral ischemia. Nimodipine has been shown in animal models to improve both postischemic CBF and neurologic outcome (Steen et aI. , 1983 (Steen et aI. , , 1984 (Steen et aI. , , 1985 . Lidoflazine, another cal cium entry blocker, has been effective in the treat ment of patients with ischemic heart disease (Gobel et aI. , 1982) and has been shown to have cardiopro tective effects in dogs (Flameng et aI. , 1981) and humans (Flameng et aI. , 1983) during cardiac isch emia. The effects of lidoflazine as a possible cere bral protective agent have also been investigated, but the reported results have been contradictory. Lidoflazine given to dogs postischemia has been re ported to either ameliorate (White et aI., 1983) or to have no effect (Dean et aI. , 1984; Vaagenes et aI. , 1984; Fleischer et aI., 1986) on the delayed post ischemic hypoperfusion state. Neurologic outcome in dogs treated with lidoflazine postischemia has been reported as improved (Winegar et aI. , 1983; Vaagenes et aI. , 1984) or not affected (Vaagenes et aI. , 1983; Fleischer et aI. , 1986) .
In a previous report from this laboratory, lidofla zine had no effect on canine postischemic CBF or neurologic outcome; however, there was a sugges tion of an improved neurologic outcome (p = 0.077) (Fleischer et aI. , 1986) . This latter result, taken together with the positive findings of other investigators (Winegar et aI. , 1983; Vaagenes et aI. , 1984) , warranted the further study of the effects of lidoflazine on neurologic outcome in a more sensi tive and relevant animal model. Accordingly, we studied the effects of lidoflazine administered after 17 min of complete cerebral ischemia, followed by 48 h of intensive care treatment and daily neuro logic evaluations for 96 h, in an established primate model.
MATERIALS AND METHODS

Study subjects and preischemic preparation
Tw elve unmedicated pigtail monkeys (Macaca nemes (rina), ages 2.5-3.5 years, of either sex, weighing 3.1-5.9 kg, were studied. The protocol was approved by the Institutional Animal Care and Use Committee. The monkeys were uniformly fed, but received only water ad libitum for the 24 h prior to the study. Monkeys were initially anesthetized with 0.5% halothane and 66% ni trous oxide in oxygen. Two milligrams of pancuronium and 0.05 mg glycopyrrolate were given i.m. to facilitate tracheal intubation with a cuffed, wire-spiral reinforced tube, and ventilation was controlled with a Harvard pump. Cannulae were placed in a right hindlimb vein for fluid administration, the abdominal aorta via the left fem oral artery for blood sampling and pressure monitoring, and the inferior vena cava via the left femoral vein for drug infusions. All monkeys received a 50-ml infusion of 5% dextrose in 0.45% normal saline 50 ± 6 min (mean ± SEM) prior to ischemia. The ECG and a two-channel, bifrontal and biparietal EEG were monitored using percu taneous needle electrodes. Body temperature was mea sured with a rectal thermistor and was maintained near 37.0°C with heating lamps and blankets. End-tidal halo thane and CO2 concentrations were monitored with a mass spectrometer (Perkin-Elmer 1100 Medical Gas Ana lyzer). Arterial blood gases were determined by elec trodes at 37"C (Instrumentation Laboratory 1303). Blood glucose was determined by a membrane-bound enzyme technique (Yellowsprings Instruments Model 23A Glu cose Analyser). Plasma sodium and potassium were mea sured with a flame photometer (Instrumentation Labora tory 443). Arterial blood gases and hemoglobin were measured immediately preischemia and frequently postischemia. Plasma sodium and potassium were mea sured preischemia, at 4-h intervals postischemia until ex tubation, at the time of extubation, and at 96 h post ischemia. Blood glucose was measured prior to, and fol lowing the preischemia dextrose infusion and frequently postischemia.
Production of ischemia
Complete cerebral ischemia was produced by a method previously described by Bleyaert et al. (1978a) and Gis voId et al. (1984) , using modifications described by Steen et al. (1985) and Lanier et al. (1986) . Halothane was dis continued for 3 min. and anesthesia was maintained with 66% nitrous oxide in oxygen. Rapid induction of hypo tension (within 1 min) was produced by administration of 20-40 mg trimethaphan i.v., until a MABP of 50 mm Hg was achieved. At this point. a collapsable neck tourni quet was abruptly inflated to 1,500 mm Hg for 17 min. and the monkeys were ventilated with 133Xe-enriched 100% O2 during the period of cerebral ischemia. A ten dency to hypertension during the first 5 min of ischemia was treated with additional administration of trimetha ph an and the addition of positive end-expiratory pressure (PEEP) to maintain MABP at 40-80 mm Hg. After 13 min of ischemia. a norepinephrine (NA) infusion was started at 0.4 fLg/kg/min and was adjusted as needed to maintain MABP at 80 mm Hg before neck tourniquet de flation. Immediately after tourniquet deflation. MABP abruptly decreased, but was rapidly restored to 80-110 mm Hg by increasing the NA infusion rate.
Completeness of cerebral ischemia was assured by the absence of cerebral blood flow monitored with 133Xe, as previously described by Steen et al. (1985) .
Postischemic treatment
Optimal life support was provided for 48 h post ischemia, with a minimum of one technician and one physician in attendance.
Five minutes postischemia, the monkeys received ei ther lidoflazine, 1.0 mg/kg i. v., or a similar volume of placebo, infused over a 10-min period. The solvent for Iidoflazine was used as the placebo. The solvent con tained (per deciliter): glacial acetic acid 0.6 ml, dextrose 4.5 g, and water. At 8 and 16 h postischemia, the same i. v. infusions of either lidoflazine or placebo were re peated. All personnel were blind to the treatment groups, except for one technician (W.G.).
Paralysis and controlled ventilation were maintained until continuous EEG activity had returned for at least 1 h. Monkeys received 100% inspired O2 until the return of continuous EEG activity; thereafter, they received 50% N20 in O2 until just prior to extubation. The N20 pro vided analgesia and sedation in an attempt to avoid a pre viously reported severe hypertensive reaction (Steen et aI., 1985; Bleyaert et aI., 1978b) . Paco2 was maintained at 25-30 mm Hg and the Pao2 was maintained above 100 mm Hg by increasing the inspired oxygen concentration Benzathine penicillin, 300,000 U, and procaine penicillin, 300,000 U, were administered i.m. daily.
As Pulsinelli et al. (1982) have shown that histologic changes after a period of ischemia require more than 24 h to mature, maximal intensive care therapy was provided for 48 h to allow brain injury time to mature. Following the 48-h neurologic evaluation, ventilatory and vaso pressor support, if still required, were gradually with drawn.
When their conditions permitted, monkeys were moved to padded open pens, and when they were judged to be near normal, they were returned to their cages. In all animals, age estimates based primarily on dentition were made by a veterinarian who was unaware of the treatment groups.
Exclusions
Animals that did not meet all preestablished protocol criteria were excluded from data analysis before the final 96-h evaluation. The decision to exclude animals was made by a blind observer (J.D.M.), who was unaware of treatment groups and of the hemodynamic response to the drug or placebo injection. Exclusion was based on strict criteria: age > 10 years; a preischemic blood glu cose >200 mg/dl: evidence of incomplete ischemia; se vere cardiopulmonary complications such as pulmonary edema, resulting in a postischemic Pao2 <60 mm Hg andl or a Paco2 >45 mm Hg; failure to achieve a postischemic MABP of >80 mm Hg within 3 min after cuff deflation; thereafter, an MABP <70 mm Hg for >60 min or of <50 mm Hg at any point, or an MABP > 130 for over I h.
Neurologic function postischemia
Neurologic function was evaluated independently at 26, 48, 72, and 96 h postischemia by two blind observers (J.E.F., J.D.M.). A previously described neurologic ex amination and scoring system was used (Steen et a!., 1985) . Briefly, this system scored monkeys according to their level of consciousness, respiration, cranial nerve function, motor and sensory function, and behavior. The results are expressed as percent neurologic function, where 100% was normal and 0% was apparent brain death. The neurologic function score was taken as the mean of the scores of the two observers.
Histopathologic evaluation
After the 96-h evaluation, the six surviving monkeys were anesthetized with 3-5 mg/kg ketamine i.m. and were paralyzed with pancuronium. The trachea was intu bated, and ventilation was controlled. A left thoracotomy was performed, and the monkeys were killed by infusing 500 ml of 4% buffered paraformaldehyde solution into the left ventricle at a pressure of 100 mm Hg, with the de scending aorta cross-clamped and the right atrium open.
One hour later, the brains were removed, weighed, and placed in 4% buffered paraformaldehyde solution.
Monkeys dying prior to the 96-h evaluation were simi larly perfused within 1 h of death. The heart and lungs of all monkeys were examined grossly postmortem to iden tify any significant pathologic findings.
Statistical evaluation
The significance of postischemic differences in neuro logic function between the two groups was evaluated by J Cereh Blood Flow Melah, Vol. 7, No.3, 1987 the two-tailed Mann-Whitney rank sum test. Differences in physiologic variables were determined by unpaired t tests. A p value of less than 0.05 was considered to be significant. All mean values are reported with the stan dard error of the mean.
RESULTS
Eleven monkeys fulfilled all protocol criteria and were therefore included in the final analysis.
Exclusions
One monkey in the lidoflazine treatment group (monkey no. 2) was excluded from the study be cause of technical difficulties with the tourniquet during the ischemic period.
Study group match
The lidoflazine-and placebo-treated groups were well matched for approximate age (2.9 ± 0.2 versus 2.8 ± 0. 1 years, respectively), body weight (4.3 ± 0. 3 versus 4.4 ± 0.4 kg, respectively), and sex (4 females and 1 male versus 5 females and 1 male, respectively).
Physiologic variables (Table 1)
There were no significant differences between Ii doflazine-treated and placebo-treated monkeys in blood gases, MABP, hemoglobin, heart rate, tem perature, blood glucose, or electrolytes when mea sured preischemia or 4 h postischemia, except for the lidoflazine-treated monkeys having a signifi cantly lower MABP preischemia (69 ± 3 versus 85 ± 3 mm Hg) and a significantly lower plasma so dium at 4 h postischemia (142 ± 1.0 versus 148 ± 1.0 meq/L). Postischemia, MABP returned to 80 mm Hg at 52 ± 15 s in the lidoflazine-treated group, compared to 42 ± 7 s postischemia in the placebo-treated group (NS). With the infusion of li doflazine at 5 min postischemia, aU 5 lidoflazine treated monkeys had slight decreases in MABP, which were readily responsive to NA therapy. Al though blind to the treatment groups, it was as sumed by those caring for the monkeys that the MABP decrease was due to Iidoflazine. At the end of the study, it became clear that this clinical sign was a reliable indicator of the treatment group in 9 of 11 monkeys. Two monkeys in the lidoflazine treated group displayed dysrhythmias that were temporally associated with the infusion of lidofla zine. These consisted variously of junctional rhythm, first-degree atrioventricular block, and ventricular tachycardia. There were no significant differences in total dosage or duration of trimetha phan or NA infusions between the two groups. Plasma Na+ (meq/L) 146 ± I 143 ± 4 142 ± la 148 ± I Plasma K + (meq/L) 3.0 ± 0.1 2.9 ± 0.2 3.7 ± 0.5 3.1 ± 0.1 a Significantly different from placebo-treated (p < 0.05). There were no significant dif ferences between the groups except for a lower MABP preischemia and a lower plasma sodium at 4 h postischemia, both in the lidoflazine-treated group. Results are expressed as mean ± SEM.
Completeness of ischemia
Cerebral ischemia was complete in all monkeys (except for the one excluded monkey). No 133Xe could be detected in any brain during ischemia.
EEG data
There were no significant differences between li doflazine-and placebo-treated groups in the time to onset of isoelectric EEG following tourniquet infla tion (20 ± 5 versus 14 ± 0 s, respectively) or time to return of either burst suppression or continuous EEG activity (60 ± 5 versus 56 ± 2 min, and 105 ± 15 versus 127 ± 16 min, respectively). In addition, there was no correlation between neurologic out come and time to return of either burst suppression or continuous EEG activity.
Seizure activity postischemia
Seizure activity on the EEG or by clinical exam was never noted during the study.
Neurologic outcome (Table 2)
There was no difference in neurologic outcome between the monkeys treated with lidoflazine or placebo by the Mann-Whitney rank sum test (p > 0.5). No monkey from either treatment group was normal at 96 h postischemia. The two monkeys having the best neurologic outcome, one from ei ther group, were unable to stand or walk at 96 h postischemia; these were the only monkeys that were judged to have normal levels of conscious ness. Over the course of 96 h, no monkey who sur vived to 96 h had any deterioration of their neuro logic status. Three lidoflazine-treated monkeys died prior to the 96-h evaluation. One died at 9 h postischemia of an apparent respiratory arrest. Prior to death, this monkey had been vocalizing and appeared to be oxygenating well. A retrospec tive neurologic function score of 61.6% was given. On postmortem exam, the dura was moderately Animal number refers to the order in which animals were studied.
a Retrospective neurologic score.
tight, and the lungs showed perihilar hemorrhagic congestion. Another died at 49. 5 h postischemia, following withdrawl of an NA infusion. The brain and lungs appeared to be grossly normal. The third monkey died at 50 h postischemia, following with drawl of ventilatory support. At postmortem exam, the dura was slightly tight, and the lungs showed perihilar hemorrhagic congestion. In the placebo treated group, two monkeys died prior to the 96-h neurologic evaluation. One died at 23 h postisch emia, following a 3-h course of deteriorating blood gases, hemodynamics, and neurologic exam. A ret rospective neurologic function score of 2. 0% was given. Postmortem, the dura was tight, with an in creased amount of CSF present. The lungs showed moderate perihilar hemorrhagic congestion. The other monkey died at 27 h postischemia, following an apparent respiratory arrest. Prior to death, this monkey was vocalizing and appeared to be oxygen ating well. At postmortem exam, the dura was very tight, and the lungs showed moderate perihilar hemorrhagic congestion. All five monkeys dying prior to the 96-h evaluation were judged to be neu rologic deaths, and thus, were not excluded from data analysis.
Histopathologic evaluation
Histopathologic evaluation was not performed because of the lack of even the suggestion of signifi cant differences in neurologic outcome between li doflazine-and placebo-treated monkeys.
DISCUSSION
Lidoflazine treatment had no beneficial effect whatsoever on neurologic outcome in monkeys fol lowing 17 min of complete cerebral ischemia. There were no significant differences between groups in factors such as body temperature, hemoglobin, age, blood gases, hemodynamics, drug solvent, or blood glucose levels, except for a physiologically unim portant lower preischemic MABP and 4-h post ischemia plasma sodium in the lidoflazine-treated animals. An MABP of 69 mm Hg with 0. 5% halo thane and 65% nitrous oxide in oxygen anesthesia is well within the autoregulatory range (Morita et al. , 1977) . The plasma sodium, although lower in the lidoflazine-treated monkeys, was within the range of normal values.
The results of the current study are in complete conflict with certain previously reported studies. Winegar et al. (1983) subjected dogs to 15 min of cardiac arrest. After resuscitation, dogs received 1.0 mg/kg lidoflazine i.v., followed by 12 h of in ten sive care treatment. Lidoflazine-treated dogs re gained brainstem function activities and showed J Cereb Blood Flow Metab, Vol. 7, No. 3, 1987 significantly better neurologic scores at 12 h post ischemia when compared to placebo-treated dogs. Vaagenes et al. (1984) evaluated neurologic status in dogs SUbjected to 10 min of ventricular fibrilla tion, followed by 1. 0 mg/kg lidoflazine i. v. 5 min postischemia and repeated at 8 and 16 h postisch emia. Dogs received 96 h of intensive care therapy. Lidoflazine-treated dogs scored significantly better neurologically than placebo-treated dogs. How ever, in a similar protocol that differed only by using an asphyxial model of cardiac arrest, Vaa genes et al. (1983) found no improvement in the neurologic outcome of lidoflazine-treated dogs as compared to placebo-treated dogs. They postulated that asphyxial arrest imposed a more severe insult, which may offset any beneficial effects of the lido flazine treatment. In a recent study (Fleischer et aI., 1986) , we found no significant effect of 1. 0 mg/kg lidoflazine (administered at 2 min, 8 h, and 16 h postischemia) on 48-h postischemia neurologic outcome in dogs following I 1 min of complete cere bral ischemia. However, there was a suggestion of an improved neurologic outcome (p = 0. 077) in the lidoflazine-treated dogs, which led to the current primate study.
Similarly the reported effects of lidoflazine on postischemic CBF have been contradictory. White et al. (1983) originally reported an improved post ischemic CBF in lidoflazine-treated dogs using an unvalidated thermodilution method. Subsequently, Dean et al. (1984) , using microspheres, and we, using a validated venous outflow technique (Fleischer et al. , 1986) , found no effect of lidofla zine on postischemic CBF. Combining these results with the neurologic outcome results, we conclude that lidoflazine improves neither postischemic CBF nor neurologic outcome. This contrasts with the re sults reported for nimodipine, which has consis tently been reported to improve postischemic CBF (Steen et aI. , 1983 (Steen et aI. , , 1984 , and, in the same primate model as used in the current study, to significantly improve neurologic outcome (Steen et al. , 1985) .
One criticism of the current study might be the relatively small number of animals studied. How ever, if six additional animals had been studied, and the three lidoflazine-treated monkeys scored 100% neurologic function while the three placebo treated monkeys scored 0% neurologic function, the results still could not achieve statistical significance. This would still be true even if the two monkeys that died prior to 24 h were excluded from data analysis.
Originally, we planned for histopathologic evalu ation of the brains. When the neurologic outcomes were known, we concluded that histopathologic evaluation was not necessary. We had already shown in two previous studies with this model that there is good correlation between neurologic func tion rank and histopathology rank (Steen et aI., 1985; Lanier et aI., 1986) . Furthermore, as Jido flazine had no significant effect on neurologic outcome, even if there were differences in histopa thology scores between lidoflazine-and placebo treated groups, the results would be uninterpret able.
In summary, we found that lidoflazine adminis tered postischemia did not improve neurologic outcome in monkeys following 17 min of complete cerebral ischemia. The present study does not support the current clinical trial of the use of lido flazine for brain resuscitation.
